Desmopressin

Desmopressin
Clinical data
Trade names	DDAVP (deamino D-arginine vasopressin), Minirin, others
AHFS/Drugs.com	Monograph
Pregnancy; category	AU: B2;
Routes of; administration	IV, IM, SC, intranasal, by mouth, under the tongue
ATC code	H01BA02 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Variable; 0.08–0.16% (by mouth)
Protein binding	50%
Elimination half-life	1.5–2.5 hours
Excretion	Kidney
Identifiers
	IUPAC name (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-; (diaminomethylideneamino)-1-oxopentan-2-yl]-1-; [(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-; (3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-; 6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-; 5,8,11,14,17-pentazacycloicosane-4-carbonyl]; pyrrolidine-2-carboxamide;
CAS Number	16679-58-6 ;
PubChem CID	5311065;
IUPHAR/BPS	2182;
DrugBank	DB00035 ;
ChemSpider	4470602 ;
UNII	ENR1LLB0FP;
KEGG	D00291 ;
ChEMBL	ChEMBL1429;
CompTox Dashboard (EPA)	DTXSID1048259 ;
ECHA InfoCard	100.037.009
Chemical and physical data
Formula	C46H64N14O12S2
Molar mass	1069.22 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc(cc1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N2)Cc3ccc(cc3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;
	InChI InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1 ; Key:NFLWUMRGJYTJIN-PNIOQBSNSA-N ;
	(what is this?) (verify)

Desmopressin, sold under the trade name DDAVP among others, is a medication used to treat diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels.^[1] In hemophilia A and von Willebrand disease, it should only be used for mild to moderate cases.^[1] It may be given in the nose, by injection into a vein, by mouth, or under the tongue.^[1]

Common side effects include headaches, diarrhea, and low blood sodium.^[1] The low blood sodium that results may cause seizures.^[1] It should not be used in people with significant kidney problems or low blood sodium.^[1] It appears to be safe to use during pregnancy.^[1] It is a synthetic analogue of vasopressin, the hormone that plays roles in the control of the body's osmotic balance, blood pressure regulation, kidney function,^[2] and reduction of urine production.^[1]

Desmopressin was approved for medical use in the United States in 1978.^[1] It is on the World Health Organization's List of Essential Medicines.^[3] It is available as a generic medication.^[1]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Desmopressin Acetate". The American Society of Health-System Pharmacists. Archived from the original on 3 December 2016. Retrieved 2 December 2016.
^ Cuzzo B, Padala SA, Lappin SL (2021). "Physiology, Vasopressin". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30252325. Retrieved 2021-06-29.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[AHFS2016-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Desmopressin Acetate". The American Society of Health-System Pharmacists. Archived from the original on 3 December 2016. Retrieved 2 December 2016.

[:0-2] Cuzzo B, Padala SA, Lappin SL (2021). "Physiology, Vasopressin". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30252325. Retrieved 2021-06-29.

[WHO21st-3] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[1]

[2]

[3]